T. Rowe Price Associates’s Travere Therapeutics TVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$1.06M Buy
71,372
+18,063
+34% +$268K ﹤0.01% 1965
2025
Q1
$956K Buy
53,309
+13,705
+35% +$246K ﹤0.01% 1979
2024
Q4
$690K Sell
39,604
-241,745
-86% -$4.21M ﹤0.01% 2132
2024
Q3
$3.94M Buy
281,349
+247,908
+741% +$3.47M ﹤0.01% 1373
2024
Q2
$275K Buy
33,441
+2,432
+8% +$20K ﹤0.01% 2456
2024
Q1
$240K Buy
31,009
+2,948
+11% +$22.8K ﹤0.01% 2535
2023
Q4
$253K Buy
28,061
+1,229
+5% +$11.1K ﹤0.01% 2447
2023
Q3
$240K Sell
26,832
-10,319
-28% -$92.3K ﹤0.01% 2432
2023
Q2
$571K Buy
37,151
+5,861
+19% +$90.1K ﹤0.01% 2057
2023
Q1
$704K Buy
31,290
+2,292
+8% +$51.6K ﹤0.01% 1958
2022
Q4
$610K Sell
28,998
-1,976
-6% -$41.6K ﹤0.01% 2042
2022
Q3
$764K Buy
30,974
+4,106
+15% +$101K ﹤0.01% 1899
2022
Q2
$651K Buy
26,868
+10,382
+63% +$252K ﹤0.01% 2095
2022
Q1
$425K Buy
16,486
+2,289
+16% +$59K ﹤0.01% 2404
2021
Q4
$441K Buy
+14,197
New +$441K ﹤0.01% 2444
2018
Q1
Sell
-286,201
Closed -$6.03M 2560
2017
Q4
$6.03M Sell
286,201
-60,500
-17% -$1.27M ﹤0.01% 1395
2017
Q3
$8.63M Buy
346,701
+1,907
+0.6% +$47.5K ﹤0.01% 1342
2017
Q2
$6.69M Sell
344,794
-155,616
-31% -$3.02M ﹤0.01% 1375
2017
Q1
$9.24M Sell
500,410
-136,900
-21% -$2.53M ﹤0.01% 1347
2016
Q4
$12.1M Sell
637,310
-211,560
-25% -$4M ﹤0.01% 1276
2016
Q3
$19M Buy
848,870
+140,181
+20% +$3.14M ﹤0.01% 1150
2016
Q2
$12.6M Sell
708,689
-15,100
-2% -$269K ﹤0.01% 1243
2016
Q1
$9.89M Buy
723,789
+5,700
+0.8% +$77.9K ﹤0.01% 1274
2015
Q4
$13.9M Sell
718,089
-2,000
-0.3% -$38.6K ﹤0.01% 1200
2015
Q3
$14.6M Sell
720,089
-27,111
-4% -$549K ﹤0.01% 1198
2015
Q2
$24.8M Hold
747,200
0.01% 1070
2015
Q1
$17.9M Buy
+747,200
New +$17.9M ﹤0.01% 1167